Having shown that the miR-1300 phenotype is consistent across a range of established and patient-derived GBM lines and that ECT2 is a promising target of miR-1300, direct targeting was confirmed using 3′UTR reporter assays. The gene discussed is ECT2; the disease is glioblastoma.